Clearstead Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

Clearstead Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-306	Closed	-$429	–	3100
2025 Q2	$429	Buy	+306	New	+$458	﹤0.01%	2506

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clearstead Advisors's ATNM Position: Q3 2025 in Review

Clearstead Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q3 2025, closing a stake of 306 shares — an estimated $429 sold.

Clearstead Advisors first reported a position in ATNM in Q2 2025 and held it in 1 quarter. The position peaked at $429 in Q2 2025. 61 funds tracked by Wall St. Rank hold ATNM as of Q3 2025.

Clearstead Advisors reported no remaining Actinium Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 306 Actinium Pharmaceuticals shares in Q3 2025, an estimated $429.
Clearstead Advisors first reported a position in Actinium Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's Actinium Pharmaceuticals position peaked at $429 in Q2 2025.
61 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.